Number of Patients With Success
| Group | Value |
|---|---|
| Calcium + Calcitriol | not posted |
| Teriparatide 20 Mcg | not posted |
| Teriparatide 40 Mcg | not posted |
| Teriparatide 60 Mcg | not posted |
Trial · Interventional
TerminatedPhase 2Results postedRegistry dataThis trial was stopped early.
Reason given at the registry: Terminated due to slow accrual.
Results were posted for this trial.
United States
1 trial · 1 stopped early · 1 with posted results
Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia
NCT00623974May 2008 to Jun 2010
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
Primary Objective: -To identify the optimal dose of a seven-day course of twice-daily teriparatide as compared to standard therapy for hypocalcemia in patients after total thyroidectomy and/or extensive neck dissections (pharyngectomy, laryngectomy,unilateral, bilateral / central neck, mediastinal lymph node neck dissections), with which serum calcium will be raised to corrected serum calcium levels of 8-10.5mg/dL and maintained within this range until the end of the treatment course.
Experimental
Calcium + Calcitriol
1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
Experimental
Teriparatide 20 mcg
Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
Experimental
Teriparatide 40 mcg
Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
Experimental
Teriparatide 60 mcg
Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
Outcomes the sponsor listed as primary.
Number of Patients With Success
Time frame · 2 - 7 days post-treatment
A patient "success" is defined as a normal calcium level (Ca\>=8 and Ca\<= 10.5) within 48 hours post-treatment initiation and a normal Ca level maintained through day 7 post-treatment initiation.
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value |
|---|---|
| Calcium + Calcitriol | not posted |
| Teriparatide 20 Mcg | not posted |
| Teriparatide 40 Mcg | not posted |
| Teriparatide 60 Mcg | not posted |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| Calcium + Calcitriol1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours | – | 0 / 0 | 0 / 0 |
| Teriparatide 20 McgTeriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours | – | 0 / 0 | 0 / 0 |
| Teriparatide 40 McgTeriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours | – | 0 / 0 | 0 / 0 |
| Teriparatide 60 McgTeriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours | – | 0 / 0 | 0 / 0 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
No study cites this trial.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated